Tuesday, January 18, 2022
10:39 AM EST – Neovasc Inc. : Announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer under a compassionate use protocol in the United States. Following the commencement of the COSIRA-II Trial in the United States, qualifying patients are now eligible to be treated in a clinical trial for the device. Neovasc Inc. (T.NVCN) shares were up $0.02 at 0.6.
Stocks in Play: Neovasc Inc. , Tue, 18 Jan 2022 10:42:06 EST